Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Shares Gap Up – Here’s Why

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) shares gapped up prior to trading on Tuesday . The stock had previously closed at $8.55, but opened at $10.30. Greenland Mines Ltd. Common Stock shares last traded at $8.9550, with a volume of 998,250 shares changing hands.

Wall Street Analysts Forecast Growth

GRML has been the subject of several recent research reports. Wall Street Zen raised Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Greenland Mines Ltd. Common Stock Price Performance

The firm has a 50-day moving average of $0.39 and a 200 day moving average of $0.41. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -33.09 and a beta of 7.13.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last announced its quarterly earnings data on Monday, August 17th. The company reported ($1.50) EPS for the quarter.

Insider Buying and Selling at Greenland Mines Ltd. Common Stock

In related news, Director Riad Hussein El-Dada sold 3,500 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.50, for a total transaction of $40,250.00. Following the transaction, the director directly owned 3,500 shares of the company’s stock, valued at approximately $40,250. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jason David Sawyer acquired 4,800 shares of the company’s stock in a transaction on Wednesday, July 22nd. The stock was acquired at an average price of $11.50 per share, with a total value of $55,200.00. Following the purchase, the director directly owned 4,800 shares in the company, valued at approximately $55,200. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Greenland Mines Ltd. Common Stock

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in shares of Greenland Mines Ltd. Common Stock in the second quarter valued at approximately $26,000. Brummer Multi Strategy AB acquired a new stake in Greenland Mines Ltd. Common Stock during the fourth quarter worth approximately $175,000. Geode Capital Management LLC increased its stake in Greenland Mines Ltd. Common Stock by 51.8% during the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after acquiring an additional 167,905 shares during the period. Renaissance Technologies LLC acquired a new position in Greenland Mines Ltd. Common Stock in the 4th quarter valued at $126,000. Finally, XTX Topco Ltd raised its holdings in Greenland Mines Ltd. Common Stock by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after acquiring an additional 80,768 shares in the last quarter. 20.07% of the stock is currently owned by institutional investors and hedge funds.

Greenland Mines Ltd. Common Stock Company Profile

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.